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Background: Circulating osteocalcin (OC), a marker which is central in bone mineralization, may be 
involved in the atherosclerotic process and influence the risk of developing cardiovascular disease 
(CVD).  
Aims: We conducted a systematic review and meta-analysis of published observational evidence, to 
assess and quantify the associations of circulating OC (total, undercarboxylated, and carboxylated 
OC) with cardiovascular outcomes (clinical CVD endpoints and intermediate cardiovascular 
phenotypes).  
Methods: Relevant studies were identified in a literature search of MEDLINE, EMBASE, and 
reference lists of relevant studies to March 2019. Mean differences and risk ratios with 95% CIs were 
aggregated using random-effects models.  
Results: Thirty-three observational studies (prospective and retrospective cohort, case-control, and 
cross-sectional) with data on 21,021 unique participants were eligible. The pooled risk ratio in a 
comparison of extreme fourths of total OC levels was 0.98 (95% CI 0.89, 1.08) for composite CVD. 
Circulating total OC levels were significantly lower in patients with cardiovascular conditions 
compared with those without these conditions -2.58 ng/ml (95% CI -3.85, -1.32; p<0.001). 
Prospective and cross-sectional data showed significant inverse associations between total OC and 
traits such as aortic or coronary calcification, coronary atherosclerosis or calcification, carotid intima-
media thickness, and plaque score. There was limited data on carboxylated and undercarboxylated 
OC, with no evidence of associations. 
Conclusion: Observational evidence generally supports inverse associations of circulating total OC 
with risk of atherosclerotic outcomes and CVD endpoints; however, the data were mostly based on 
cross-sectional evaluations. Large-scale prospective data are needed.  
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Cardiovascular disease (CVD) is still the leading cause of global mortality.(1) By 2030, an estimated 
23.6 million people will die from CVD.(2) Major risk factors for CVD include a history of diabetes, 
high blood pressure, raised blood lipids, as well as smoking status.(3) Though these established risk 
factors explain a large proportion of the risk of CVD, its pathogenesis is still not fully established as it 
appears other additional factors may be involved. Osteocalcin (OC), a bone matrix protein mainly 
expressed by osteoblasts(4) and used as a biochemical indicator of bone formation,(5) has been 
proposed as a potential biomarker of CVD risk. Osteocalcin is secreted by osteoblasts in a fully 
carboxylated form, which is then decarboxylated to a more active biological form (4, 6, 7). 
Circulating blood levels of total OC comprises both carboxylated and undercarboxylated OC. Serum 
OC has been investigated as a hormone which  plays a role in regulating glucose metabolism and fat 
mass; it promotes insulin sensitivity and secretion by pancreatic β-cells, as well as increases 
proliferation of  the β-cells and stimulates energy metabolism.(6) Reduced circulating levels of OC 
have been consistently linked with high blood glucose levels, insulin resistance, and type 2 
diabetes.(6, 8-10). Indeed, it has been discussed that OC may hold potential for the prevention, delay 
and treatment of obesity and metabolic disorders such as diabetes.(8) Emerging evidence also 
suggests circulating OC may be involved in CVD development, but the data are sparse and 
conflicting. A number of studies have shown reduced levels of circulating OC to be associated with 
adverse cardiovascular outcomes such as arterial calcification, carotid atherosclerosis, increased 
carotid intima-media thickness (CIMT), and CVD;(11-13) whereas others have not demonstrated any 
relationships.(14, 15). In this context, we performed a systematic review and meta-analysis of all 
available published observational evidence to clarify and quantify the extent of potential associations 
of circulating OC (total, uncarboxylated, and carboxylated OC) with (i) clinical CVD outcomes as 
well as all-cause mortality; and (ii) intermediate cardiovascular traits. We also sought to identify gaps 







Data sources and search strategy 
This review was conducted using a predefined protocol and in accordance with PRISMA and 
MOOSE guidelines (16, 17) (Appendix 1-2). We searched MEDLINE and EMBASE up to 22 March 
2019. The computer-based searches combined terms related to the exposure (e.g., “osteocalcin”) and 
outcomes (e.g., “cardiovascular disease”, “coronary heart disease”, “atherosclerosis”, “carotid intima-
media thickness”, “mortality”) in humans, without any language restriction. Reference lists of selected 
studies and relevant reviews on the topic were manually scanned for additional publications missed by 
the original search. Full details on the search strategy are presented in Appendix 3.  
 
Eligibility criteria 
We systematically searched for observational cohort, case-control, or cross-sectional population-based 
studies that had reported on associations of circulating levels of OC (total OC, undercarboxylated OC, 
and carboxylated OC) with (i) CVD-related outcomes [composite CVD, coronary heart disease 
(CHD), stroke, congestive heart failure (CHF), or all-cause mortality]; and (ii) intermediate 
cardiovascular traits [carotid atherosclerosis, aortic atherosclerosis, coronary artery calcification 
(CAC), carotid intima-media thickness (CIMT), abdominal aortic calcification (AAC)].  
 
Data extraction and quality assessment  
The titles and abstracts of all articles identified by the broad literature search were assessed 
independently by two reviewers (SKK and SS). Studies that did not meet inclusion criteria were 
discarded. Full text of selected articles were retrieved and assessed to determine if they met the 
inclusion criteria. Those studies which met the inclusion criteria were included in the review and data 
was extracted independently by two reviewers (SKK and SS) using a standard data extraction form. 





When available, data were extracted on: publication date; study design; geographical location; 
population source; year of baseline survey; sample population; mean/median age at baseline; duration 
of follow-up (for cohort studies); type of OC; mean/median levels of OC; type of outcome; and 
reported risk estimates. In the case of multiple publications involving the same study, data were 
extracted from the most up-to-date study or study with the most comprehensive information was 
abstracted. We also corresponded with study investigators to provide missing information where 
relevant. Any discrepancies regarding eligibility of an article were discussed, and consensus reached 
with a third reviewer (K.K.). For cohort and case-control studies, study quality was assessed based on 
the nine-star Newcastle–Ottawa Scale (NOS) (18) using three pre-defined domains namely: selection 
of participants (population representativeness), comparability (adjustment for confounders), and 
ascertainment of outcomes of interest. The NOS assigns a maximum of four points for selection, two 
points for comparability, and three points for outcome. Nine points on the NOS reflects the highest 
study quality. For cross-sectional studies, quality was evaluated using the NOS modified for cross-
sectional studies (Appendix 4(10)). A score of 8 reflected the highest study quality.  
  
Statistical analysis 
Mean differences for continuous outcomes and risk ratios for categorical outcomes were used as 
summary measures across studies. A narrative synthesis was performed for studies that could not be 
pooled. For data reported as medians, standard errors, ranges, and 95% confidence intervals (CIs), 
means and standard deviations were estimated using methods as described by Hozo and colleagues 
(19). To enable a consistent approach to the meta-analysis, enhance comparability and interpretation 
of the findings, units of measurements were converted where appropriate and reported study-specific 
risk ratios (per-unit or standard deviation change, quintiles, or other groupings) were also transformed 
to involve comparisons between the top quartile and bottom quartile of each study population’s 
baseline distribution of OC levels, using standard statistical methods.(20, 21) described 





inverse variance weighted method to combine summary measures using random-effects models.(25) 
We evaluated for publication bias using funnel plots and Egger’s regression symmetry tests (26). All 
tests were two-tailed and p-values of 0.05 or less were considered significant. STATA release 14 
(Stata Corp, College Station, Texas, USA) was used for all statistical analyses. 
 
Results 
Study identification and selection 
165 potentially relevant citations were identified. 40 articles were selected for full text evaluation after 
an initial screen based on titles and abstracts. After detailed assessments, 8 articles were excluded 
because (i) the outcomes were not relevant to review (n=5); (ii) the exposure was not relevant (n=2); 
and (ii) one article used the same population sample as another study included in the review. The 
remaining 32 articles based on 33 unique observational studies met all inclusion criteria and were 
included in the review (Figure 1; Appendix 5).  
 
Study characteristics and study quality 
Table 1 shows a summary of the key characteristics of the included. 21,021 unique participants were 
included in this review. However, not all studies provided relevant data that could be included in the 
quantitative synthesis. The majority of studies (n=19) were conducted in Asia (China, Japan, and 
South Korea); with 10 in Europe (Austria, France, Germany, Italy, The Netherlands, and Spain); 2 in 
the Pacific (Australia); and 2 in North America (USA). The mean/median baseline age of participants 
ranged from 49 to 77 years. The majority of studies (n=20) were cross-sectional in design; 9 
prospective cohorts; 2 case-controls; 1 retrospective cohort and 1 prospective case-control. The 
average follow-up for cohort studies ranged from 0.5 to 10.0 years. For studies that provided relevant 
data on their recruitment processes, majority of studies (n=22) reported recruiting patients from 
healthcare settings, with 7 studies reporting recruitment from a population register. There was 





participants, post-menopausal women, and patients with pre-existing conditions such as type 2 
diabetes, chronic kidney disease, essential hypertension and those at high cardiovascular risk. Among 
cohort, case-control, and cross-sectional studies, quality score ranged from 3 to 8.  
 
Association of circulating osteocalcin with cardiovascular outcomes 
Cohort analysis The pooled risk ratio of 5 cohort studies (3481 participants and 686 events) for 
composite CVD risk comparing individuals in the top versus bottom fourths of circulating total OC 
levels, adjusted for several established cardiovascular risk factors was 0.98 (95% CI 0.89, 1.08; 
p=0.669) (Figure 2). The prospective corresponding risk ratios for CHD and stroke based on results 
of a single study were 1.06 (95% CI 0.38, 2.93) and 0.65 (95% CI 0.29, 1.46) respectively.  
In pooled analysis of 2 prospective studies (1,760 participants and 378 events), the multivariate-
adjusted risk ratio for all-cause mortality was 0.33 (95% CI 0.03, 3.51; p=0.355) comparing 
individuals in the top versus bottom fourths of circulating total OC levels. Four studies could not be 
included in the meta-analysis because of differences in the exposure categories. In analysis adjusted 
for several conventional risk factors, Yeap and colleagues reported a U-shaped relationship of 
circulating total OC with CVD mortality and all-cause mortality in men – the risk being increased at 
both ends of the distribution of OC levels.(27). In a follow-up of the same study that evaluated CHD 
and stroke outcomes, total OC was not associated with MI or stroke events.(15) In the Ludwigshafen 
Risk and Cardiovascular Health (LURIC) prospective cohort study,(28) findings reported in men 
showed a U-shaped association of total OC with fatal CVD and all-cause mortality -  with increased 
risk at both ends of the distribution of OC levels. In a prospective case-control study of 102 MI 
patients and 200 control subjects, total OC was demonstrated to be associated with premature MI at 
one-year follow-up.(29)  
In the single prospective cohort study that evaluated the associations between undercarboxylated OC 
and cardiovascular endpoints, there was no evidence of an association of undercarboxylated OC with 





Cross-sectional analysis Comparing individuals in the top versus bottom fourths of circulating total 
OC levels, the multivariate-adjusted risk ratio for CHD in pooled analysis of 3 cross-sectional studies 
(766 participants and 383 events) was 1.20 (95% CI 0.32, 4.50; p=0.789). 
 
Association of serum total osteocalcin with intermediate cardiovascular traits 
Cohort analysis The pooled risk ratio for aortic calcification in pooled analysis of 2 prospective 
cohort studies was 0.87 (95% CI 0.76, 0.99; p=0.030) comparing individuals in the top versus bottom 
fourths of circulating total OC levels. In a prospective cohort study that monitored changes in total 
OC and plaque score in Japanese patients with type 2 diabetes, changes in circulating total OC was 
inversely associated with changes in plaque score from baseline in analysis adjusted for 
atherosclerotic risk factors (β=-0.30; p=0.047).(30) 
 
Cross-sectional analysis In pooled analysis of 8 studies (3356 participants), the multivariate-adjusted 
risk ratio for vascular atherosclerosis or calcification when comparing individuals in the top versus 
bottom fourths of circulating total OC levels was 0.67 (95% CI 0.37, 1.22; p=0.187) (Figure 3). The 
risk ratio for vascular atherosclerosis or calcification when comparing individuals in the top versus 
bottom fourths of circulating undercarboxylated OC levels in pooled analysis of 4 studies (762 
participants) was 0.76 (95% CI 0.13, 4.63; p=0.767) (Figure 3).  
Five studies could not be included in the meta-analysis. Kanazawa and colleagues in their 
assessment of the associations of serum total OC with atherosclerosis parameters in patients with type 
2 diabetes, total OC was significantly and inversely correlated with CIMT in men (r=-0.181; 
p=0.023), but not in women (r=0.022; p=0.803).(31) In a sample of 817 men and postmenopausal 
women with type 2 diabetes, serum total OC was independently and inversely associated with CIMT 
(β=-0.181; r=-0.187; p<0.001).(12) Yang and colleagues also demonstrated a significant and inverse 
association between serum total OC and CIMT (β=-0.117; r=-0.107; p<0.01)(13). Kim and colleagues 





measured by the aortic calcium score (r=-0.238; p<0.001).(11) An independent and inverse 
correlation (β=-0.497; p=0.003) was also demonstrated between serum total OC and coronary 
atherosclerosis index in the study by Bao and colleagues.(32) 
 
Circulating osteocalcin levels in patients with cardiovascular outcomes and traits compared 
with controls 
The pooled random-effects mean difference across 9 studies showed significantly lower circulating 
levels of total OC -2.58 ng/ml (95% CI -3.85, -1.32; p<0.001) in patients with cardiovascular 
conditions compared to subjects without cardiovascular conditions (Figure 4). In pooled analysis of 4 
studies, there was no significant difference in circulating undercarboxylated OC levels comparing 
subjects with and without cardiovascular conditions. In a case-control study, circulating carboxylated 
OC level was significantly lower comparing subjects with and without CAD -0.50 ng/ml (95% CI -
0.71, -0.29; p<0.001). 
 
Discussion 
Summary of findings 
Using a systematic and meta-analytical approach, we have summarized all available observational 
studies that have assessed the associations of circulating levels of OC (total, undercarboxylated, and 
carboxylated OC) with clinical CVD endpoints and intermediate CVD traits, in an attempt to address 
the uncertainties in the evidence. In the analysis of hard CVD outcomes, pooled analysis of 
prospective data showed no evidence of statistically significant associations of total OC with 
composite CVD, CHD, or stroke endpoints. However, two prospective studies conducted in men 
demonstrated a U-shaped association of total OC with fatal CVD and all-cause mortality.(27, 28) 
Both low and high levels of total OC were associated with an increased risk of these outcomes. In the 
evaluation of intermediate cardiovascular traits, prospective data showed significant inverse 





evidence from cross-sectional studies was inconsistent, majority of studies reported inverse, 
independent, and significant correlations between total OC and outcomes such as CIMT, aortic 
calcification, and coronary calcification or atherosclerosis. Circulating total OC was significantly 
lower in patients with cardiovascular conditions compared with those without these conditions. The 
data was limited for undercarboxylated and carboxylated OC and generally no significant evidence of 
associations were demonstrated with the outcomes assessed. 
 
Interpretation of findings 
The current evidence does not conclusively support a role of circulating OC (particularly total OC) in 
the pathophysiology of adverse cardiovascular lesions as well as CVD risk. Though some of the 
findings show that reduced levels of circulating total OC are associated with greater pathological 
cardiovascular changes, there was evidence to suggest that increased levels of total OC might also be 
associated with increased risk of these adverse outcomes. Beyond its well-established pro-osteoblastic 
functions(33), OC has been demonstrated to have endocrine functions.(6) Consistent evidence shows 
that reduced circulating levels of OC is associated with increased risk of adverse metabolic outcomes 
such as type 2 diabetes and metabolic syndrome (MetS), which is via its role in influencing insulin 
secretion, glucose metabolism, insulin sensitivity, fat mass, beta cell proliferation, and energy 
expenditure.(6, 34, 35) Though the mechanistic evidence has mostly involved the use of animal 
models, recent epidemiological and genetic studies suggest the multiple aspects of the biology of OC 
are similar for both humans and rodents. (36, 37) However, the mechanistic evidence linking OC with 
atherosclerotic CVD is unclear compared with metabolic conditions such as type 2 diabetes; a number 
of pathways have been proposed. Conditions such as insulin resistance, metabolic syndrome, non-
alcoholic fatty liver disease, and type 2 diabetes, which are closed linked to circulating OC, accelerate 
the progression of atherosclerotic lesions and are strongly linked to the development of 
atherosclerosis.(12) Osteocalcin may be involved in the calcification process at arterial and valvular 





play a direct role in the atherosclerotic process, as osteoclast-like cells have been identified in 
atherosclerotic lesions.(39) Whether the different forms of OC may play different roles in the 
pathophysiology of adverse cardiovascular outcomes is not clear, as the evidence has mostly been 
limited to circulating total OC. However, there is evidence from animal models suggesting that  
undercarboxylated OC, the more active form of OC, may be of more importance in regulating glucose 
and energy metabolism(6, 34, 40) and therefore could be implicated in the development of adverse 
metabolic outcomes.  This is not well established as it is not even certain if undercarboxylated OC 
might be the active form in humans (36).  
 
Implications of findings 
The current findings provide further insight on the role of OC beyond its pro-osteoblastic properties as 
well as its role in glucose and energy metabolism. The clinical use of circulating OC assays has 
mainly been for monitoring and assessing the effectiveness of antiresorptive therapy in patients with 
bone conditions characterised by elevated OC levels such as osteoporosis and Paget’s disease.(41) 
Though some of the findings were inconsistent which impeded meaningful interpretation, the overall 
results of the quantitative synthesis of the available data does not underscore a potentially protective 
role of increased circulating total OC levels on the risk of atherosclerotic lesions and CVD outcomes. 
The inconsistencies in the findings could be related to the small sample sizes employed by majority of 
studies, different populations used, different OC assay methods employed, and the fact that circulating 
OC levels are influenced by ethnicity, gender and menopausal status.(42) There is some suggestion 
from our results that there may be a more evident association in males. In addition to highlighting the 
lack of consistent evidence on the cardiovascular effects of OC, this review has also identified several 
gaps in the literature. Compared with the number of cross-sectional study designs (n=20), only 10 
observational cohort studies were identified to have evaluated the associations and these were limited 
by small sample sizes and populations with pre-existing disease. Furthermore, the majority of studies 





observation could be attributed to the fact that circulating total OC can be conveniently measured in 
large studies using automated immunoassays (43), while assays for undercarboxylated OC are more 
cumbersome, labour intensive, or less precise (44). Large-scale prospective studies conducted in 
general population settings are needed to address the existing research gaps. Thus far, the potential of 
strategies that raise concentrations of circulating total OC and their value in the prevention or 
treatment of vascular diseases is not convincing enough. This is a topic which deserves further 
investigation. 
 
Strengths and limitations 
The strengths and limitations of this systematic meta-analysis merit careful consideration. The notable 
strengths included the comprehensive search strategy which yielded several published studies on the 
topic. Overall, this review involved over 21,000 participants and evaluated a wide-range of 
atherosclerotic and CVD outcomes and their relationships with the different forms of circulating OC. 
We were able to transform reported risk estimates from majority of contributing studies to a consistent 
comparison (mean differences and top versus bottom fourths) to allow a consistent combination of 
estimates across studies, therefore obtaining a reliable estimate of the magnitude of the association 
and enhancing interpretation of the overall findings. We also conducted a detailed quality assessment 
of eligible studies. Limitations included the inability to fully examine the impact of adjustment for 
potential confounding factors, because the review was based on variably adjusted data reported in the 
published literature; heterogeneity could not be explored because of the limited number of studies 
available for pooling; and some outcomes and risk estimates were inconsistent between studies and 
therefore could not be pooled.  
In conclusion, aggregate observational data do not generally support inverse and independent 
associations of circulating total OC with risk of atherosclerotic outcomes and CVD endpoints; 





literature and large-scale prospective cohort studies are needed to explore the nature and potential 
magnitude of any association of circulating OC with cardiovascular outcomes. 
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Figure 1. Selection of studies included in the meta-analysis 
 
 




CI, confidence interval (bars); OC, osteocalcin 
 
 
Figure 3. Associations of circulating total and undercarboxylated osteocalcin with intermediate 
cardiovascular traits 
 
AAC, abdominal aortic calcification; CAC, coronary artery calcification; CI, confidence interval 
(bars); OC, osteocalcin 
 
 
Figure 4. Mean differences in circulating osteocalcin levels comparing subjects with cardiovascular 
conditions and their respective controls 
 
 
CAC, coronary artery calcification; CAD, coronary artery disease; CHD, coronary heart disease; 






165 Potentially relevant citations identified
From MEDLINE, EMBASE, Web of Science 
and reference list of relevant studies
125 excluded on the basis of title 
and/ or abstract




32 Articles included, based on 33 
unique observational studies
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Table 1. Characteristics of studies included in review 
Lead Author, 
Publication Date  
 






















































             
Jie, 1995 Population-based Netherlands Cross-sectional Post-menopausal 1990 66.6* 0.0 NA Aortic atheroclerosis 113 NA 4 
Schleithoff, 2003 Health setting Germany Case-control CHF patients and 
controls 
2000-2001 66.2-71.5* 100.0 NA CHF 42 NA 4 
Montalcini, 2004 Hospital clinic Italy Cross-sectional Post-menopausal 
women 
NR 45-75 0.0 NA Carotid atherosclerosis 157 Age, hypertension, hyperlipidemia, type 2 diabetes, 
obesity, smoker 
6 




2003 62.7* NR NA Carotid/femoral 
atherosclerosis 
66 NA 5 





NA CIMT 179 
149 
Age, duration of diabetes, BMI, serum creatinine, 




Okura, 2010 NR Japan Cross-sectional Essential hypertension NR 61.0* 58.0 NA CAC 92 NR 4 
Parker, 2010 SOF USA Cross-sectional Community-dwelling 
postmenopausal 
1986-1988 ≥ 65 0.0 NA AAC 363 Age, body mass index, systolic and diastolic blood 
pressure, diabetes, hypertension, smoking history, eGFR, 
CRP, estrogen use, intact parathyroid hormone, bone-
specific alkaline phosphatase, and 25-hydroxyvitamin D; 
hip and spine bone mineral density 
6 
Zhang, 2010 NR China Cross-sectional Subjects referred for 
coronary angiography 
2005-2007 39-85 64.9 NA CHD 461 Age, gender, BMI, smoking, alcohol, family history of 
CHD, LDL-C, HDL-C, TG, type 2 diabetes 
6 
Bao, 2011 Hospital China Cross-sectional Coronary angiography 
patients 
2008-2009 64.9* 100.0 NA Coronary 
artherosclerosis index 
181 Age, BMI, fasting insulin, HbA1c, HOMA-IR 6 
Goliasch, 2011 Hospital setting Austria Case-control MI patients with 
controls 
2004-2008 ≤40 88.7 NA NA 302 NA 8 
Kanazawa, 2011 NR Japan Prospective cohort Type 2 diabetes NR 64.5* 56.0 0.5 Plaque score 50 Duration of diabetes, Brinkman Index 5 
Kim, 2012 SBMS South Korea Cross-sectional Subjects referred for 
QCT 






Publication Date  
 






















































Reyes-Garcia, 2012 Endocrinology Unit Spain Cross-sectional Type 2 diabetes 2006-2007 57.8* 55.1 NA CHD 78 Age, gender, BMI, hypt, smoking, DM duration, aortic 
calcifications, abnormal IMT, carotid plaques 
6 
Yeap, 2012 HIMS Australia Prospective cohort Community-dwelling 
elderly men 
2001-2004 77.0* 100.0 5.2 CVD, all-cause 
mortality 
3,542 Age, WHR, conventional CVD risk factors 8 
Confavreux, 2013 MINOS France Prospective cohort Elderly men 1995-1996 51-85 100.0 10 AAC, all-cause 
mortality 
774 Age, diabetes, hip to waist ratio, hypertension, smoking 
status, alcohol intake, serum phosphate, low HDL-
cholesterol, AAC score, physical activity, and 25OHD 
7 
Lerchbaum, 2013 LURIC Germany Prospective cohort Suspected CAD 1997-2000 58.72 100.0 7.7 CVD mortality, all-
cause mortality 
2,271 Age, BMI, smoking, WHR, CETP, hs-CRP, 
homocysteine, interleukin-6, HDL cholesterol, LDL 




Hospital Japan Cross-sectional Type 2 diabetes 2005-2011 64.0* 54.1 NA AAC 218 Age, BMI, creatinine, LDL-C, radial BMD, smoking, 
duration of DM, HbA1c, HOMA-IR, BAP, UNTx 
6 
Sheng, 2013 Shanghai 
downtown 
residential areas 
China Cross-sectional Type 2 diabetes NR >50 46.8 NA Carotid 
atherosclerosis, CIMT 
817 Age, sex, smoking, alcohol, family history of diabetes, 
WC, HOMA-IR, BMI, WHR, TG, TC, HDL-C, LDL-C, 
CRP, treatments 
6 
Yamashita, 2013 Outpatient dialysis 
center 
Japan Prospective cohort Maintenance 
haemodialysis patients 
2005 20-85 61.1 5.0 CVD 126 Age, sex, time on dialysis, previous CVD, diabetes, serum 
Calcium x phosphate product, serum parathyroid hormone 
levels 
7 
Yang, 2013  SOS China Cross-sectional Post-menopausal 
women 
NR 41-78 0.0 NA CIMT 1,319 Age, years since menopause, BMI, WC, SBP, DBP, 
HOMA-IR, TG, HDL-C, CRP, smoking, treatment, 
family history of CVD 
7 
Holvik, 2014 LASA Netherlands Prospective cohort Elderly participants 1995-1996 65-88 48.8 4.1 CVD, ACS 832 Age, BMI, SBP, TG, TC, HDL-C, fructosamine 8 
Lerchbaum, 2014 LURIC Germany Prospective cohort Suspected CAD 1997-2000 58.72 0.0 7.7 CVD mortality, all-
cause mortality 
986 Age, BMI, menopause, prevalent CAD, HRT, vitamin K 
antagonist use 
8 
Ma, 2014 Shangai Changfeng 
study 
China Cross-sectional Middle-aged and 
elderly 
2009-2012 61.3* 100.0 NA Carotid atherosclerosis 1,077 Age, FPG, PPG, BMI, WHR, smoking, SBP, DBP, TG, 
HDL-C, LDL-C, HOMA-IR, HOMA-B 
7 
Choi, 2015 Hospital South Korea Cross-sectional Asymptomatic patients 2010-2012 53.5 70.4 NA CAC 162 Age, body mass index, smoking (menopause), 
hypertension, diabetes, systolic blood pressure, HOMA2-
IR, triglycerides, HDL cholesterol and lumbar BMD 
6 
Hwang, 2015 HPC Korea Prospective cohort Middle-aged men 1997 40-78 100.0 8.7 Composite CVD, 
CHD, stroke 
1,290 Age, BMI, current smoking, LDL-C, diabetes, 







Publication Date  
 






















































Maser, 2015 Diabetes and 
Metabolic Research 
Center 
USA Cross-sectional Type 2 diabetes NR ≥ 18 42.0 NA CAC 50 NA 5 
Yeap, 2015 HIMS Australia Prospective cohort Community-based men 2001-2004 70-89 100.0 NA CHD, stroke 3,384 Education, smoking, BMI, WHR, hypertension, 
dyslipidemia, diabetes, creatinine, vitamin D, prevalent 
CVD, cancer 
7 
Zhang, 2015 Hospital China Cross-sectional Non-dialysis with CKD NR 50-75 62.9 NA Carotid atherosclerosis 240 Age, sex, BMI, smoking history, MABP, eGFR, 
therapeutic medication use, and FBG, TC, TG, LDL-C, 
HDL-C, and hs-CRP levels 
6 
Kim, 2016 Hospital South Korea Cross-sectional Patients who 
underwent CABG 
2012--2013 60.7* 100.0 NA Coronary artery 
stenosis 
122 NA 5 




2014-2016 40-60 100.0 NA Carotid atherosclerosis 335 NA 3 
Ling, 2018 Hospital China Cross-sectional Post-menopausal 
women with CAD and 
controls 
2015-2016 66.0* 0.0 NA CHD, coronary 
atherosclerosis 
227 Age, BMI, smoking, hypertension, diabetes, LDL-C, 
HDL-C, TG, eGFR, statin use and high-sensitivity CRP 
5 
Zhang, 2018 Hospital China Retrospective cohort Coronary angiography 
patients 
2008-2009 65.5* 66.4 4.4 CVD 247 Age, BMI, WC, SBP, DBP, FPG, 2hPG, HOMA-IR, TG, 
HDL-C, LDL-C, CRP, current smoker 
6 
 
AAC, abdominal aortic calcification; ACS, aortic calcification score; BMD, bone mineral density; BMI, body mass index; CABG, coronary artery bypass graft; CAC, coronary artery calcification; CAD, coronary 
artery disease; CHD, coronary heart disease; CHF, congestive heart failure; CKD, chronic kidney disease; CIMT, carotid artery intima-media thickness; CRP, C-reactive protein; CVD, cardiovascular disease; DBP, 
diastolic blood pressure; eGFR, estimated glomerular filtration rate, FPG, fasting plasma glucose; HDL-C, high-density lipoprotein cholesterol; HIMS, Health In Men Study; HOMA-B, homeostasis model assessment 
of beta cell function; HOMA-IR, homeostasis model assessment of insulin resistance; HPC, Health Promotion Center; LASA, Longitudinal Aging Study Amsterdam; LDL-C, low-density lipoprotein cholesterol; MI, 
myocardial infarction; NA, not applicable; NR, not reported; SBMS, Severance Bone Metabolism study; SBP, systolic blood pressure; SOF, Study of Osteoporotic Fractures; SOS, Shangai Obesity Study; TC, total 









Appendix 1 PRISMA checklist 
Appendix  2 MOOSE checklist 
Appendix  3 MEDLINE literature search strategy 
Appendix  4 Modified Newcastle Ottawa Quality Scale for cross-sectional studies 



















2 Provide a structured summary including, as applicable, background, objectives, data sources, study 
eligibility criteria, participants, interventions, study appraisal and synthesis methods, results, limitations, 
conclusions and implications of key findings, systematic review registration number 
2 
Introduction 
Rationale 3 Describe the rationale for the review in the context of what is already known 3 
Objectives 4 Provide an explicit statement of questions being addressed with reference to participants, interventions, 





5 Indicate if a review protocol exists, if and where it can be accessed (such as web address), and, if 
available, provide registration information including registration number 
4 
Eligibility criteria 6 Specify study characteristics (such as PICOS, length of follow-up) and report characteristics (such as 




7 Describe all information sources (such as databases with dates of coverage, contact with study authors to 
identify additional studies) in the search and date last searched 
4 
Search 8 Present full electronic search strategy for at least one database, including any limits used, such that it 
could be repeated 
Appendix 3 
Study selection 9 State the process for selecting studies (that is, screening, eligibility, included in systematic review, and, if 




10 Describe method of data extraction from reports (such as piloted forms, independently, in duplicate) and 
any processes for obtaining and confirming data from investigators 
5 
Data items 11 List and define all variables for which data were sought (such as PICOS, funding sources) and any 
assumptions and simplifications made 
5 
Risk of bias in 
individual studies 
12 Describe methods used for assessing risk of bias of individual studies (including specification of whether 





13 State the principal summary measures (such as risk ratio, difference in means). 5-6 
Synthesis of results 14 Describe the methods of handling data and combining results of studies, if done, including measures of 
consistency (such as I2 statistic) for each meta-analysis 
5-6 
Risk of bias across 
studies 
15 Specify any assessment of risk of bias that may affect the cumulative evidence (such as publication bias, 
selective reporting within studies) 
6 
Additional analyses 16 Describe methods of additional analyses (such as sensitivity or subgroup analyses, meta-regression), if 
done, indicating which were pre-specified 
6 
Results 
Study selection 17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for 
exclusions at each stage, ideally with a flow diagram 




18 For each study, present characteristics for which data were extracted (such as study size, PICOS, follow-
up period) and provide the citations 
6-7, Table 1 
Risk of bias within 
studies 
19 Present data on risk of bias of each study and, if available, any outcome-level assessment (see item 12). 7, Table 1 
Results of 
individual studies 
20 For all outcomes considered (benefits or harms), present for each study (a) simple summary data for 
each intervention group and (b) effect estimates and confidence intervals, ideally with a forest plot 
7-10 
Synthesis of results 21 Present results of each meta-analysis done, including confidence intervals and measures of consistency 7-10, Figures 
2-4 
Risk of bias across 
studies 
22 Present results of any assessment of risk of bias across studies (see item 15) 7, Table 1 
Additional analysis 23 Give results of additional analyses, if done (such as sensitivity or subgroup analyses, meta-regression) 





24 Summarise the main findings including the strength of evidence for each main outcome; consider their 
relevance to key groups (such as health care providers, users, and policy makers) 
10-11 
Limitations 25 Discuss limitations at study and outcome level (such as risk of bias), and at review level (such as 
incomplete retrieval of identified research, reporting bias) 
12-13 




Funding 27 Describe sources of funding for the systematic review and other support (such as supply of data) and 






Appendix 2. MOOSE checklist  
 
Association of circulating osteocalcin with cardiovascular disease and 




Criteria Brief description of how the criteria were handled in the 
review 
Reporting of background   
 Problem definition The data on the associations of circulating osteocalcin (OC) with 
cardiovascular disease (CVD) are sparse and conflicting. In this 
context, we have carried out a comprehensive systematic meta-
analysis to quantify the associations of circulating OC (total, 
undercarboxylated, and carboxylated with cardiovascular outcomes 
(clinical CVD endpoints and intermediate cardiovascular 
phenotypes).  
 
 Hypothesis statement Circulating levels of OC are associated with cardiovascular outcomes 
 Description of study outcomes CVD-related outcomes [composite CVD, coronary heart disease 
(CHD), stroke, congestive heart failure (CHF), or all-cause 
mortality]; and (ii) intermediate cardiovascular traits [carotid 
atherosclerosis, aortic atherosclerosis, coronary artery calcification 
(CAC), carotid intima-media thickness (CIMT), abdominal aortic 
calcification (AAC)].  
 
 Type of exposure  Blood circulating levels of OC (total OC, undercarboxylated OC, and 
carboxylated OC 
 Type of study designs used Observational cohort, case-control, or cross-sectional population-
based studies 
 Study population Healthy participants, pre- and post-menopausal women, as well as 
participants with pre-existing conditions such as metabolic 
syndrome, type 2 diabetes, and participants at high cardiovascular 
risk 
Reporting of search strategy should 
include 
 
 Qualifications of searchers Samuel Seidu, MD; Setor Kunutsor, PhD 
 Search strategy, including time 
period included in the synthesis and 
keywords 
Time period: from inception of MEDLINE and EMBASE to 22 March 
2019.  
Search strategy: 
The detailed search strategy can be found in Appendix 3. 
 Databases and registries searched MEDLINE and EMBASE 
 Search software used, name and 
version, including special features 
OvidSP was used to search EMBASE 
EndNote used to manage references  
 Use of hand searching We searched bibliographies of retrieved papers  
 List of citations located and those 
excluded, including justifications 
Details of the literature search process are outlined in the flow chart.  
The citation list for excluded studies is available upon request. 
 Method of addressing articles 
published in languages other than 
English 
We placed no restrictions on language 
 Method of handling abstracts and 
unpublished studies 
Not applicable 
 Description of any contact with 
authors 
We contacted authors who had conducted univariate or multivariate 
analysis with osteocalcin as an exposure and cardiovascular 
outcomes but had not reported relevant estimates. 
Reporting of methods should include  
 Description of relevance or 
appropriateness of studies assembled 
for assessing the hypothesis to be 
tested 
Detailed inclusion and exclusion criteria are described in the Methods 
section. 





coding of data population characteristics, study design, exposure, outcome, and 
possible effect modifiers of the association. 
 Assessment of confounding We assessed confounding by ranking individual studies on the basis 
of different adjustment levels.  
 Assessment of study quality, 
including blinding of quality 
assessors; stratification or regression 
on possible predictors of study 
results 
Study quality was assessed based on the nine-star Newcastle–
Ottawa Scale using pre-defined criteria namely: population 
representativeness, comparability (adjustment of confounders), 
ascertainment of outcome.  
 Assessment of heterogeneity Limited data precluded assessment of heterogeneity 
 Description of statistical methods in 
sufficient detail to be replicated 
Description of methods of meta-analyses and assessment of 
publication bias are detailed in the methods. We performed random 
effects meta-analysis with Stata 14. 
 Provision of appropriate tables and 
graphics 
See Figures 2-4; Table 1 
Reporting of results should include  
 Graph summarizing individual study 
estimates and overall estimate 
Figures 2-4 
 Table giving descriptive information 
for each study included 
Table 1  
 Results of sensitivity testing 
 
NA 
 Indication of statistical uncertainty of 
findings 
95% confidence intervals were presented with all summary 
estimates 
Reporting of discussion should include  
 Quantitative assessment of bias The systematic review is limited in scope, as it involves published 
data. Individual participant data is needed. Limitations have been 
discussed. 
 
 Justification for exclusion All studies were excluded based on the pre-defined inclusion criteria 
in methods section. 
 Assessment of quality of included 
studies 
Brief discussion included in ‘Methods’ section 
Reporting of conclusions should 
include 
 
 Consideration of alternative 
explanations for observed results 
We discussed that potential unmeasured confounders may have 
caused residual confounding. Additionally, our findings could have 
been over-estimated somewhat due to preferential publication of 
extreme findings. The variations in the strengths of association may 
also be due to true population differences, or to differences in quality 
of studies. 
 Generalization of the conclusions Discussed in the context of the results. 
 Guidelines for future research We recommend large-scale prospective data 







Appendix 3. MEDLINE literature search strategy 
 
1     exp OSTEOCALCIN/bl [Blood] (3992) 
2     exp Cardiovascular Diseases/ (2257611) 
3     exp Coronary Disease/ (209108) 
4     exp Coronary Artery Disease/ (56488) 
5     exp STROKE/ 120515 () 
6     exp ATHEROSCLEROSIS/ (38589) 
7     exp Carotid Intima-Media Thickness/ (4196) 
8     exp Vascular Calcification/ (3505) 
9     aortic calcification.mp. (1019) 
10     exp MORTALITY/ (356269) 
11     exp Heart Failure/ (112241) 
12     2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 (2536035) 
13     1 and 12 (155) 
14     limit 13 to (humans and "all adult (19 plus years)") (126) 
 











The methodological quality score is based on New-Castle Ottawa Quality Scale and is adapted for this review. 
Maximum of one star can be awarded for each item in Selection and Outcome categories. A maximum of two 
stars can be given for Comparability items. 
 
Cut-off scores 
Low methodological quality 0-3 stars 
Moderate methodological quality 4-6 stars 
High methodological quality 7-8 stars (>75%) 
 
Category 1: Selection 
 
1. Representativeness of the sample 
(a) Truly representative if the sample is randomly derived from the general population with sample size of 
>100 subjects * 
(b) Somewhat representative sample from the population with sample size of >100* 
(c) Selected group of users (e.g., nurses, volunteers) 
(d) No description of the derivation of the cases. 
 
2. Non-respondents 
(a) Comparability between respondents and non-respondents characteristics is established, and the response 
rate is satisfactory* 
(b) The response rate is unsatisfactory, or the comparability between respondents and non-respondents is 
unsatisfactory 
(c) No description of the response rate or the characteristics of the responders and the non-responders 
 
3. Adequate definition of exposure 
(a) Yes, according to a clear and widely used definition * 
(b) Yes, from record linkage or based on self-reports 
(c) No description. 
 
4. Ascertainment of exposure 
(a) Secure record* 
(b) Written self-report 
(c) No description 
 
 
Category 2: Comparability 
 
5. Comparability on the basis of the design/analysis 
(a) Study controls for age, sex, or BMI* 
(b) Study controls for any additional factor: Smoking status, education, alcohol intake, physical activity, lipids, 
or blood pressure)* 
 
 
Category 3: Outcome  
 
6. The study used a precise definition of outcome and valid and reliable method (individually for each relevant 
outcome) 
 
7. Assessment of outcome  
(a) Independent blind assessment (reference to medical records)* 
(b) Record linkage (coded by ICD on database records)* 
(c) Self-report. 
(d) No description. 
 
8. Statistical test 
(a) The statistical test used to analyse the data is clearly described and appropriate, and the measurement of 
the association is present, including confidence intervals and the probability level (p-value)* 
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